Fucoidan/bis-MPA-based dendrimer nanoparticles with intrinsic anti-angiogenic activity for oncology applications

Abstract

Nanoparticles with intrinsic anti-angiogenic activity hold strong promise in cancer nanomedicine, as they can both help suppress metastasis and deliver therapeutics, offering a dual strategy for addressing the disease. In this study, fucoidans from F. vesiculosus and U. pinnatifida with two different molecular weights (MW) of each were initially screened for in vitro anti-angiogenic potential using the tube formation assay with HUVEC cells. The higher MW fucoidans, which represent native MW fucoidan, exhibited greater anti-angiogenic activity and were subsequently combined with 2,2-bis(hydroxymethyl)propionic acid (bis-MPA)-based dendrimers (generation 2) at different fucoidan/dendrimer (F/D) mass ratios to form self-assembled nanoparticles through electrostatic interactions. Optimisation yielded two nanoparticle types with positive (F/D = 1 : 2) and negative (F/D = 2 : 1) zeta potentials, which were characterised for their physicochemical properties, including hydrodynamic diameter, zeta potential, chemical composition (FTIR), and morphology (TEM). These nanoparticles presented a near-spherical shape, were cytocompatible, and did not cause haemolysis. Positively charged nanoparticles showed stronger anti-angiogenic activity than negatively charged ones. Since the dendrimers alone were also anti-angiogenic, the overall effect likely results from the combined contribution of both components, with nanoparticle assembly potentially playing a role. Overall, these findings highlight the potential of fucoidan/dendrimer nanoparticles as multifunctional platforms for cancer nanomedicine, by targeting angiogenesis and potentially serving as drug or gene delivery systems.

Graphical abstract: Fucoidan/bis-MPA-based dendrimer nanoparticles with intrinsic anti-angiogenic activity for oncology applications

Supplementary files

Article information

Article type
Paper
Submitted
02 Dec 2025
Accepted
06 Feb 2026
First published
12 Feb 2026
This article is Open Access
Creative Commons BY license

RSC Pharm., 2026, Advance Article

Fucoidan/bis-MPA-based dendrimer nanoparticles with intrinsic anti-angiogenic activity for oncology applications

F. Olim, A. Duarte, A. R. Neves, I. Rodriguez-Clemente, J. T. Kidgell, B. C. Wimmer, V. Ceña and H. Tomás, RSC Pharm., 2026, Advance Article , DOI: 10.1039/D5PM00362H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements